Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Therapeutic MRI-HIFU Ablation of Uterine Fibroids in a 3T MRI Scanner

This study has been completed.
Philips Medical Systems
Information provided by (Responsible Party):
Philips Healthcare Identifier:
First received: February 5, 2010
Last updated: December 3, 2012
Last verified: December 2012
This study is to collect supplementary safety and technical effectiveness data of Philips MRI guided High Intensity Focused Ultrasound (HIFU) in ablating uterine tissue associated with symptomatic fibroids in a 3T MRI scanner. The importance of this therapy is that it offers a non-invasive, uterine sparing procedure for the treatment of uterine fibroids in pre- and peri- menopausal women. MRI guided high intensity focused ultrasound uses ultrasound to heat and thermally ablate fibroid tissue. The MRI system identifies the ultrasound path and monitors heat rise in the fibroid tissue. The goal of the study is to collect supplementary 3T treatment safety and technical effectiveness data in a 1 month follow-up study. MRguided HIFU will be performed in patients who pass inclusion/exclusion criteria. Safety, quality of life, and imaging endpoints will be evaluated in all study patients.

Condition Intervention Phase
Uterine Leiomyomas
Device: Philips MR-guided HIFU system
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Clinical Trial Protocol for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids in a 3T MRI Scanner

Further study details as provided by Philips Healthcare:

Primary Outcome Measures:
  • Safety of HIFU for treatment of the uterine fibroids as determined by adverse event reporting. [ Time Frame: 30 days after treatment ]
    Number of adverse events reported in the study divided by the total number of treated subjects.

  • Technical efficacy of HIFU for treatment of uterine fibroids as assessed by a change in the Symptom Severity Score [ Time Frame: 30 days after treatment ]
    Mean absolute change in the Symptom Severity Score (SSS) of the uterine Fibroid Symptoms Quality of Life questionnaire from baseline to 30 days after treatment.

Secondary Outcome Measures:
  • Change in Quality of Life Scores [ Time Frame: 30 days after treatment ]
    Mean absolute score change in the Quality of Life questionnaire from baseline to 30 days after treatment.

  • Pain score [ Time Frame: 72 hours after treatment ]
    Mean Visual Analog Score (VAS) for pain 72 hours after treatment.

  • Timeframe before returning to daily activities [ Time Frame: 72 hours after treatment ]
    Mean timeframe for the patient to return to normal activity after treatment.

Enrollment: 7
Study Start Date: January 2010
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treated leiomyomas
Pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure are treated with the Philips MR-guided HIFU system. Patients must have completed child bearing prior to enrolling in this study.
Device: Philips MR-guided HIFU system
HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
Other Names:
  • Sonalleve
  • Uterine Leiomyomas
  • Fibroids
  • HIFU
  • Ablation
  • High Intensity Focused Ultrasound

  Show Detailed Description


Ages Eligible for Study:   18 Years to 59 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women, age between 18 and 59 years
  • Weight < 140kg
  • Pre- or peri-menopausal
  • Uterine size < 24 weeks
  • Transformed SSS score > 40
  • Normal Cervical cell assessment by PAP
  • Symptomatic Fibroid disease
  • Dominant fibroid greater than or equal to 3cm and less than or equal to 12 cm

Exclusion Criteria:

  • Other Pelvic Disease
  • Desire for future pregnancy
  • Significant systemic disease even if controlled
  • Positive pregnancy test
  • Hematocrit < 25%
  • Scarring or other interference of the HIFU beam
  • MRI or contrast contraindicated
  • Fibroids not quantifiable on MRI
  • Calcifications around or throughout uterine tissues
  • Communication barrier
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01064960

Oslo University Hospital
Oslo, Norway
Sponsors and Collaborators
Philips Healthcare
Philips Medical Systems
Principal Investigator: Erik Fosse, Professor Oslo University Hospital
  More Information

Responsible Party: Philips Healthcare Identifier: NCT01064960     History of Changes
Other Study ID Numbers: 997677
Study First Received: February 5, 2010
Last Updated: December 3, 2012

Keywords provided by Philips Healthcare:
Neoplasms, Connective and Soft Tissue
Neoplasms, Muscle Tissue
Neoplasms by Histologic Type
Connective Tissue Diseases
Neoplasms, Connective Tissue

Additional relevant MeSH terms:
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Connective Tissue Diseases processed this record on May 23, 2017